Canada markets open in 1 hour 45 minutes

NOXXON Pharma N.V. (ALNOX.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
0.2360-0.0082 (-3.36%)
As of 01:22PM CET. Market open.
Full screen
Previous Close0.2442
Open0.2450
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2358 - 0.2450
52 Week Range0.2100 - 0.5360
Volume78,131
Avg. Volume1,400,727
Market Cap16.018M
Beta (5Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • Business Wire

    NOXXON Pharma N.V.: Half-yearly Report on the Liquidity Contract With Invest Securities

    BERLIN, January 26, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that pursuant to the liquidity contract entrusted to Invest Securities by NOXXON Pharma N.V. the following assets appeared on the liquidity account:

  • Business Wire

    NOXXON Provides Progress Update on the Expansion Arms of the Phase 1/2 GLORIA Trial With NOX-A12 in Brain Cancer Patients

    BERLIN, January 07, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that the Data Safety Monitoring Board (DSMB) positively evaluated safety data from the initial four weeks of treatment of the first patient enrolled in the GLORIA clinical trial expansion arm with NOX-A12 combined with radiotherapy and bevacizumab. The DSMB conclude

  • Business Wire

    NOXXON Provides Update on Evaluation of NOX-A12 in Non-Oncology Indication by a Leading International Pharma Company

    BERLIN, January 05, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that the evaluation of NOX-A12 by a leading international pharmaceutical company in a non-oncology indication announced on June 24, 2019 has been completed. The pharmaceutical company has decided not to pursue further work with NOX-A12 in this field and to terminate the collabora